- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.06. | WuXi AppTec hits back after being named in Pentagon's Chinese military list | ||
| 09.06. | GSK doubles down on oncology with $10.6bn Nuvalent takeover | ||
| 09.06. | J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline | ||
| 09.06. | Pfizer's Hympavzi secures FDA expanded indications for haemophilia | ||
| 09.06. | J&J secures extended NICE approval for Darzalex following earlier refusal | ||
| 08.06. | Incyte bolsters haematology portfolio in $2bn Vega buyout | ||
| 08.06. | Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics | ||
| 08.06. | ADA26: key obesity readouts from the conference | ||
| 08.06. | Sanofi and Owkin partner to develop next-generation biopharma AI agents | ||
| 08.06. | EC grants marketing authorisation for IntraBio's Aqneursa | ||
| 05.06. | Parabilis eyes $475m IPO to push lead asset into Phase III | ||
| 05.06. | Pfizer signs licence agreement with Chai for AI drug discovery | ||
| 05.06. | Biogen's salanersen gains FDA breakthrough therapy designation for SMA | ||
| 04.06. | Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership | ||
| 04.06. | Cellares and TScan to assess automated manufacturing of TSC-101 therapy | ||
| 04.06. | Regeneron and CytomX extend cancer therapy partnership to $4bn deal | ||
| 03.06. | US lawmakers reveal policy to curb collaboration with Chinese biotech | ||
| 03.06. | Contraline secures $92.5m to push male contraceptive into late-stage trials | ||
| 03.06. | AbbVie receives EC approval for Aquipta to treat migraine | ||
| 03.06. | Roche's giredestrant secures FDA priority review for breast cancer | ||
| 02.06. | ASCO26: In vivo oncology approaches continue to show promise | ||
| 02.06. | ASCO26: Blood cancer readouts take centre stage | ||
| 02.06. | BMS secures FDA acceptance for Camzyos sNDA | ||
| 02.06. | Servier to acquire Edgewise's muscular dystrophy business for $2.65bn | ||
| 01.06. | ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.